The P140K mutant of human O6-methylguanine-DNA-methyltransferase (MGMT) confers resistance in vitro and in vivo to temozolomide in combination with the novel MGMT inactivator O6-(4-bromothenyl)guanine

Journal of Gene Medicine

Volumn 8, Issue 1, 2006, Pages 29-34

  Woolford, Lorna B ^a   Southgate, Thomas D ^a   Margison, Geoffrey P ^a   Milsom, Michael D ^a   Fairbairn, Leslie J ^a  

^a CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Chemoprotection; Gene therapy; MGMT; O6 benzylguanine; PaTrin 2

Indexed keywords

6 O BENZYLGUANINE; ANTINEOPLASTIC AGENT; LOMEGUATRIB; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; RETROVIRUS VECTOR; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CELL STRAIN K 562; COLONY FORMING CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; FLUORESCENCE ACTIVATED CELL SORTING; GENE THERAPY; GENE TRANSFER; GENETIC CODE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TUMOR RESISTANCE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE THERAPY; GUANINE; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUTATION; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA;

EID: 31544441555     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.816     Document Type: Article

References (26)

1. Lewis C. A review of the use of chemoprotectants in cancer chemotherapy. Drug Safety 1994; 11: 153-162.
2. Margison GP, O'Connor PJ. Biological consequences of reactions with DNA: role of specific lesions. In Handbook of Experimental Pharmacology, Cooper CS, Grover PL (eds). Springer: Berlin, 1990; 547-571.
3. Dolan ME, Pegg AE. 06-Benzylguanine and its role in chemotherapy. Clin Cancer Res 1997; 3: 837-847.
4. Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci U S A 1990; 87: 5368-5372.
5. Dolan ME, Pegg AE, Moschel RC, et al. Effect of O6-benzylguanine on the sensitivity of human colon tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU). Biochem Pharmacol 1993; 46: 285-290.
6. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995; 55: 2853-2857.
7. Fairbairn LJ, Watson AJ, Rafferty JA, et al. O6-Benzylguanine increases the sensitivity of human primary bone marrow cells to the cytotoxic effects of temozolomide. Exp Hematol 1995; 23: 112-116.
8. Gerson SL, Phillips W, Kastan M, et al. Human CD34+ hematopoietic progenitors have low, cytokine-unresponsive O6-alkylguanine-DNA alkyltransferase and are sensitive to O6-benzylguanine plus BCNU. Blood 1996; 88: 1649-1655.
9. Chinnasamy N, Rafferty JA, Hickson I, et al. O6-Benzylguanine potentiates the in vivo toxicity and clastogenicity of temozolomide and BCNU in mouse bone marrow. Blood 1997; 89: 1566-1573.
10. Friedman HS, Pluda J, Quinn JA, et al. Phase I trial of carmustine plus O6-benzlguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol 2000; 18: 3522-3528.
11. Quinn JA, Pluda J, Dolan ME, et al. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol 2002; 20: 2277-2283.
12. Xu-Welliver M, Kanugula S, Pegg AE. Isolation of human O6-alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine. Cancer Res 1998; 58: 1936-1945.
13. Hickson I, Fairbairn LJ, Chinnasamy N, et al. Protection of mammalian cells against chloroethylating agent toxicity by an O6-benzylguanine-resistant mutant of human O6-alkylguanine-DNA alkyltransferase. Gene Ther 1996; 3: 868-877.
14. Davis BM, Reese JS, Koc ON, et al. Selection for G156A O6-methylguanine DNA methyltransferase gene-transduced hematopoietic progenitors and protection from lethality in mice treated with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea. Cancer Res 1997; 57: 5093-5099.
15. Hickson I, Fairbairn LJ, Chinnasamy N, et al. Chemoprotective gene transfer I: transduction of human haemopoietic progenitors with O6-benzylguanine-resistant O6-alkylguanine-DNA alkyltransferase attenuates the toxic effects of O6-alkylating agents in vitro. Gene Ther 1998; 5: 835-841.
16. Chinnasamy N, Rafferty JA, Hickson I, et al. Chemoprotective gene transfer II: multilineage in vivo protection of haemopoiesis against the effects of an antitumour agent by expression of a mutant human O6-alkylguanine-DNA alkyltransferase. Gene Ther 1998; 5: 842-847.
17. Ragg S, Xu-Welliver M, Bailey J, et al. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res 2000; 60: 5187-5195.
18. Koc ON, Reese JS, Davis BM, et al. DeltaMGMT-transduced bone marrow infusion increases tolerance to O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea and allows intensive therapy of 1,3-bis(2-chloroethyl)-1-nitrosourea-resistant human colon cancer xenografts. Hum Gene Ther 1999; 10: 1021-1030.
19. Middleton MR, Kelly J, Thatcher N, et al. O(6)-(4Bromothenyl) guanine improves the therapeutic index of temozolomide against A375M melanoma xenografts. Int J Cancer 2000; 85: 248-252.
20. Middleton MR, Thatcher N. McMurry TB, et al. Effect of O6-(4bromothenyl) guanine on different temozolomide schedules in a human melanoma xenograft model. Int J Cancer 2002; 100: 615-617.
21. Milsom MD, Woolford LB, Margison GP, et al. Enhanced in vivo selection of bone marrow cells by retrovira-lmediated coexpression of mutant O6-methylguanine-DNA-methyltransferase and HOXB4. Mol Ther 2004; 10: 862-873.
22. Watson AJ, Margison GP. O6-Alkylguanine-DNA alkyltransferase assay. Methods Mol Biol 2000; 152: 49-61.
23. Hildinger M, Eckert HG, Schilz AJ, et al. FMEV vectors: both retroviral long terminal repeat and leader are important for high expression in transduced hematopoietic cells. Gene Ther 1998; 5: 1575-1579.
24. Ryan MD, Drew J. Foot-and-mouth disease virus 2A oligopeptide mediated cleavage of an artificial polyprotein. EMBO J 1994; 13: 928-933.
25. Brent TP, von Wronski MA, Edwards CC, et al. Identification of nitrosourea-resistant human rhabdomyosarcomas by in situ immunostaining of O6-methylguanine-DNA methyltransferase. Oncol Res 1993; 5: 83-86.
26. Lee SM, Margison GP, Woodcock AA, et al. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma. Br J Cancer 1993; 67: 1356-1360.